The University of Chicago Header Logo

Connection

Richard A. Larson to Survival Rate

Back to Details
This is a "connection" page, showing publications Richard A. Larson has written about Survival Rate.
Richard A. Larson
Connection Strength
1.667
Survival Rate
  1. Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial. Leukemia. 2021 09; 35(9):2539-2551.
    View in: PubMed
    Score: 0.140
  2. Imatinib is still recommended for frontline therapy for CML. Blood Adv. 2018 12 26; 2(24):3648-3652.
    View in: PubMed
    Score: 0.120
  3. Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance). Blood Adv. 2018 07 24; 2(14):1705-1718.
    View in: PubMed
    Score: 0.117
  4. Long-term outcomes for newly-diagnosed multiple myeloma patients treated with pegylated liposomal doxorubicin and bortezomib: final results of CALGB (Alliance) 10301, a multicentre phase II study. Br J Haematol. 2015 Nov; 171(3):373-7.
    View in: PubMed
    Score: 0.095
  5. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer. 2005 Oct 01; 104(7):1442-52.
    View in: PubMed
    Score: 0.048
  6. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood. 2005 Jan 01; 105(1):49-53.
    View in: PubMed
    Score: 0.044
  7. Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin). Leukemia. 2002 Sep; 16(9):1627-36.
    View in: PubMed
    Score: 0.039
  8. Tipifarnib as maintenance therapy did not improve disease-free survival in patients with acute myelogenous leukemia at high risk of relapse: Results of the phase III randomized E2902 trial. Leuk Res. 2021 12; 111:106736.
    View in: PubMed
    Score: 0.037
  9. Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results. Leukemia. 2022 01; 36(1):90-99.
    View in: PubMed
    Score: 0.036
  10. Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202. Leukemia. 2021 10; 35(10):2854-2861.
    View in: PubMed
    Score: 0.036
  11. Biomarkers associated with blinatumomab outcomes in acute lymphoblastic leukemia. Leukemia. 2021 08; 35(8):2220-2231.
    View in: PubMed
    Score: 0.035
  12. Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia. Blood Adv. 2021 01 26; 5(2):504-512.
    View in: PubMed
    Score: 0.035
  13. Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. Leukemia. 2021 02; 35(2):440-453.
    View in: PubMed
    Score: 0.035
  14. Transplantation in adults with relapsed/refractory acute lymphoblastic leukemia who are treated with blinatumomab from a phase 3 study. Cancer. 2019 Dec 01; 125(23):4181-4192.
    View in: PubMed
    Score: 0.031
  15. Evaluation of event-free survival as a robust end point in untreated acute myeloid leukemia (Alliance A151614). Blood Adv. 2019 06 11; 3(11):1714-1721.
    View in: PubMed
    Score: 0.031
  16. Outcome for pediatric acute promyelocytic leukemia patients at Children's Oncology Group sites on the Leukemia Intergroup Study CALGB 9710 (Alliance). Pediatr Blood Cancer. 2019 03; 66(3):e27542.
    View in: PubMed
    Score: 0.030
  17. A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111. Blood. 1998 Sep 01; 92(5):1556-64.
    View in: PubMed
    Score: 0.029
  18. Telomere Length Recovery: A Strong Predictor of Overall Survival in Acute Promyelocytic Leukemia. Acta Haematol. 2016; 136(4):210-218.
    View in: PubMed
    Score: 0.026
  19. Maintenance therapy with decitabine in younger adults with acute myeloid leukemia in first remission: a phase 2 Cancer and Leukemia Group B Study (CALGB 10503). Leukemia. 2017 01; 31(1):34-39.
    View in: PubMed
    Score: 0.026
  20. Treatment of acute myeloid leukemia with antecedent myelodysplastic syndrome. Leukemia. 1996 Apr; 10 Suppl 1:S23-5.
    View in: PubMed
    Score: 0.025
  21. Overexpression and knockout of miR-126 both promote leukemogenesis. Blood. 2015 Oct 22; 126(17):2005-15.
    View in: PubMed
    Score: 0.024
  22. Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapy. Biol Blood Marrow Transplant. 2015 Mar; 21(3):559-64.
    View in: PubMed
    Score: 0.023
  23. Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients. Haematologica. 2014 Aug; 99(8):1373-9.
    View in: PubMed
    Score: 0.022
  24. Recombinant interleukin-2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: results from Cancer and Leukemia Group B 19808. Cancer. 2014 Apr 01; 120(7):1010-7.
    View in: PubMed
    Score: 0.021
  25. Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American Intergroup Phase II study SWOG S0432. Leuk Res. 2014 Mar; 38(3):329-33.
    View in: PubMed
    Score: 0.021
  26. Intensive induction is effective in selected octogenarian acute myeloid leukemia patients: prognostic significance of karyotype and selected molecular markers used in the European LeukemiaNet classification. Haematologica. 2014 Feb; 99(2):308-13.
    View in: PubMed
    Score: 0.021
  27. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood. 2013 Jun 13; 121(24):4854-60.
    View in: PubMed
    Score: 0.020
  28. Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. Leukemia. 2013 Jan; 27(1):107-12.
    View in: PubMed
    Score: 0.019
  29. Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: results of Cancer and Leukemia Group B Study 19802. Cancer. 2013 Jan 01; 119(1):90-8.
    View in: PubMed
    Score: 0.019
  30. FLT3 mutation status is a predictor of early death in pediatric acute promyelocytic leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2012 Oct; 59(4):662-7.
    View in: PubMed
    Score: 0.019
  31. The MLL partial tandem duplication in adults aged 60 years and older with de novo cytogenetically normal acute myeloid leukemia. Leukemia. 2012 Jul; 26(7):1713-7.
    View in: PubMed
    Score: 0.019
  32. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol. 2011 Sep; 12(9):841-51.
    View in: PubMed
    Score: 0.018
  33. Low expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemia. Blood. 2011 Oct 13; 118(15):4188-98.
    View in: PubMed
    Score: 0.018
  34. Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720. Leukemia. 2011 May; 25(5):800-7.
    View in: PubMed
    Score: 0.017
  35. Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712. J Clin Oncol. 2011 Apr 01; 29(10):1349-55.
    View in: PubMed
    Score: 0.017
  36. Therapy for acute myeloid leukemia and acute lymphoblastic leukemia in adults. Curr Opin Oncol. 1991 Feb; 3(1):30-8.
    View in: PubMed
    Score: 0.017
  37. Does microgranular variant morphology of acute promyelocytic leukemia independently predict a less favorable outcome compared with classical M3 APL? A joint study of the North American Intergroup and the PETHEMA Group. Blood. 2010 Dec 16; 116(25):5650-9.
    View in: PubMed
    Score: 0.017
  38. BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Blood. 2010 Dec 16; 116(25):5660-9.
    View in: PubMed
    Score: 0.017
  39. High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: Cancer and Leukemia Group B study 19902. Leuk Res. 2011 Mar; 35(3):329-33.
    View in: PubMed
    Score: 0.017
  40. Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy. Leukemia. 2010 Jul; 24(7):1299-301.
    View in: PubMed
    Score: 0.017
  41. P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808. Blood. 2010 Sep 02; 116(9):1413-21.
    View in: PubMed
    Score: 0.017
  42. Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study. J Clin Oncol. 2010 Feb 01; 28(4):596-604.
    View in: PubMed
    Score: 0.016
  43. High rates of durable response are achieved with imatinib after treatment with interferon alpha plus cytarabine: results from the International Randomized Study of Interferon and STI571 (IRIS) trial. Haematologica. 2009 Dec; 94(12):1669-75.
    View in: PubMed
    Score: 0.016
  44. Allogeneic stem cell transplantation with alemtuzumab-based conditioning for patients with advanced chronic myelogenous leukemia. Leuk Lymphoma. 2009 Jan; 50(1):85-91.
    View in: PubMed
    Score: 0.015
  45. Pretreatment C-reactive protein is a predictor for outcomes after reduced-intensity allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2008 Nov; 14(11):1209-16.
    View in: PubMed
    Score: 0.015
  46. An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia. Blood. 2008 Nov 15; 112(10):4193-201.
    View in: PubMed
    Score: 0.015
  47. A phase II study of continuous infusion homoharringtonine and cytarabine in newly diagnosed patients with chronic myeloid leukemia: CALGB study 19804. Cancer Chemother Pharmacol. 2009 Apr; 63(5):859-64.
    View in: PubMed
    Score: 0.015
  48. Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720. J Clin Oncol. 2008 Oct 20; 26(30):4934-9.
    View in: PubMed
    Score: 0.015
  49. Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B study. J Clin Oncol. 2008 Oct 01; 26(28):4603-9.
    View in: PubMed
    Score: 0.014
  50. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia. 2008 Jun; 22(6):1200-6.
    View in: PubMed
    Score: 0.014
  51. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006 Dec 07; 355(23):2408-17.
    View in: PubMed
    Score: 0.013
  52. Performance status and comorbidity predict transplant-related mortality after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2006 Sep; 12(9):954-64.
    View in: PubMed
    Score: 0.013
  53. Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. Blood. 2006 Jul 01; 108(1):63-73.
    View in: PubMed
    Score: 0.012
  54. Abnormal cytogenetics at date of morphologic complete remission predicts short overall and disease-free survival, and higher relapse rate in adult acute myeloid leukemia: results from cancer and leukemia group B study 8461. J Clin Oncol. 2004 Jun 15; 22(12):2410-8.
    View in: PubMed
    Score: 0.011
  55. Prognostic importance of TLX1 (HOX11) oncogene expression in adults with T-cell acute lymphoblastic leukaemia. Lancet. 2004 Feb 14; 363(9408):535-6.
    View in: PubMed
    Score: 0.011
  56. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003 Mar 13; 348(11):994-1004.
    View in: PubMed
    Score: 0.010
  57. A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: results from CALGB Study 9211. Leukemia. 2003 Feb; 17(2):323-7.
    View in: PubMed
    Score: 0.010
  58. Isolated trisomy of chromosomes 8, 11, 13 and 21 is an adverse prognostic factor in adults with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. Int J Oncol. 2002 Nov; 21(5):1041-51.
    View in: PubMed
    Score: 0.010
  59. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood. 2002 May 15; 99(10):3530-9.
    View in: PubMed
    Score: 0.010
  60. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol. 2001 Jul 01; 19(13):3244-54.
    View in: PubMed
    Score: 0.009
  61. High-energy total body irradiation as preparation for bone marrow transplantation in leukemia patients: treatment technique and related complications. Int J Radiat Oncol Biol Phys. 1998 Jan 15; 40(2):391-6.
    View in: PubMed
    Score: 0.007
  62. Long-term survival of patients with intermediate and high grade lymphoma treated with COMLA/ABP. Leukemia. 1990 Feb; 4(2):127-31.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.